the purposes of this article are to describe the events that led to the approval of this indication for cholestyramine ( but not for the other hypolipidemics ) , to explore the factors that primary health care practitioners should consider in the management of hypercholesterolemia and to anticipate future developments in hypolipidemic therapy .
C0008402
cholestyramine
C0020443
hypercholesterolemia